Evicenter
MarkdownMedical informationP&T meetings

Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Section 2 of 6

Executive summary

12 evidence topics · 70 sources

Clinical benefits of Palazestrant

Burden of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Summary: incidence, prevalence, recurrence, and survival

In the United States in 2026, an estimated 321,910 new cases of invasive breast cancer will be diagnosed in women and 2,670 in men, and an estimated 42,670 breast cancer deaths (42,140 in women, 530 in men) will occur. In SEER data, the HR+/HER2- subtype had an age-adjusted rate of 92.9 new cases per 100,000 women (2019 to 2023 cases) and accounted for 70% of female breast cancer cases; 6% of female breast cancer cases were distant stage at diagnosis. Of an estimated 50,344 new diagnoses of metastatic breast cancer in 2013, 12,966 (26%) were de novo and 37,378 (74%) were recurrences. A second model estimated 46,666 new metastatic female breast cancer cases (de novo and recurrence) in 2018 and projected 52,126 in 2025. In a separate analysis, breast cancer recurrences occurred at a steady rate throughout the study period from 5 to 20 years, and the risk of distant recurrence ranged from 13% with T1N0 disease to 41% with T2N4–9 disease.

An estimated 138,622 women were living with metastatic breast cancer in the United States in 2013, and 154,794 were projected by January 1, 2017. The second model estimated 140,230 individuals living with metastatic female breast cancer on January 1, 2018 and projected 169,347 on January 1, 2025. A separate estimate found that 61% of women living with metastatic breast cancer were originally diagnosed with stage I to III disease. Five-year relative survival for HR+/HER2- female breast cancer was 100.0% for localized, 91.1% for regional, and 38.1% for distant stage, compared with 33.8% for distant-stage female breast cancer of all subtypes. The female breast cancer death rate was 18.9 per 100,000 women per year (2020 to 2024, age-adjusted). In HR+/HER2- metastatic breast cancer, median breast cancer-specific survival was 39 months in the post-2015 group and 35 months in the pre-2015 group (hazard ratio 0.896), with 48-month rates of 44.5% and 38.5%. Treatment of metastatic disease is “palliative in intent”.

Summary: endocrine resistance, ESR1 mutations, and outcomes after a first-line CDK4/6 inhibitor

Most HR-positive breast cancers that benefit from first-line endocrine therapy eventually become endocrine-resistant, and second-line endocrine monotherapy has a median progression-free survival of 2 to 6 months, compared with 1 to 4 years for first-line endocrine therapy. About 50% of endocrine resistance cases are associated with an ESR1 mutation. Approximately 20% to 40% of patients who have received aromatase inhibition for metastatic breast cancer have ESR1 mutations, which occur “almost exclusively after AI in the metastatic setting”; in one cohort, ESR1 mutation prevalence was 5.8% (3 of 52) among participants first exposed to an aromatase inhibitor in the adjuvant setting and 36.4% (16 of 44) among those first exposed in the metastatic setting. In real-world genomic testing, ESR1 mutation prevalence in tissue biopsies collected within 60 days of the start of first-, second-, and third-line therapy was 8.1% (175 of 2,154), 27.1% (73 of 269), and 33.3% (72 of 216); in liquid biopsies with a tumor fraction of 1% or more it was 17.5% in first line and 59% in third line. A PI3K/AKT pathway alteration was present in 55.1%, 48.3%, and 54.6% of tissue biopsies in the same three lines, and both an ESR1 mutation and a PI3K/AKT pathway alteration in 4.4%, 8.2%, and 17.1%.

In BOLERO-2, 156 of 541 evaluable participants (28.8%) had an ESR1 D538G and/or Y537S mutation; overall survival was 32.1 months with wild-type ESR1, 25.99 months with D538G, 19.98 months with Y537S, and 15.15 months with both mutations. Loss of ER expression occurs in approximately 10% of endocrine-resistant breast cancers, and one analysis reported that 60% of endocrine-resistant metastatic breast cancers lacked known somatic drivers of resistance. In a cohort of 839 participants who received a second-line therapy after progression on a first-line CDK4/6 inhibitor, median real-world progression-free survival was 3.71 months with chemotherapy, 3.25 months with fulvestrant monotherapy, 3.32 months with everolimus, and 8.25 months with a second-line CDK4/6 inhibitor. A systematic review of 18 studies of second-line treatment after a first-line CDK4/6 inhibitor calculated a weighted average median real-world progression-free survival of 3.9 months for single-agent endocrine therapy, 3.6 months for an mTOR inhibitor with or without endocrine therapy, and 6.1 months for chemotherapy; no study reported disaggregated outcomes in the third-line setting or beyond.

Summary: humanistic burden and health-related quality of life

In a cross-sectional survey of physicians and their patients with HR+/HER2- metastatic breast cancer in Europe and the United States (August 2022 to February 2023), 298 physicians provided data on 1,642 participants, of whom 321 self-reported data. Tiredness (85.6%), general worry (75.9%), and worry about future health (75.9%) were the most common patient-reported symptoms and side effects; physicians reported bone pain (30.3%) as the most frequent symptom and estimated that 55.1% of participants experienced no side effects, and low patient-physician concordance was “associated with worse HRQoL”. In a study of 739 participants and 173 oncologists, the mean health utility index was 0.73 overall; it was 0.62 with visceral and bone metastases, 0.68 with bone-only metastases, and 0.78 with visceral-only metastases, and 0.81, 0.63, and 0.40 with mild, moderate, and severe worst pain. Moderate or extreme anxiety/depression was reported by 66.7% of participants receiving chemotherapy and 53.1% of those receiving endocrine therapy. In a standard gamble study of 100 members of the general public, stable disease on treatment had a utility of 0.72, with a gain of 0.07 after a treatment response, a decline of 0.27 for disease progression, and declines of 0.10 to 0.15 for toxicities.

Among 152 participants in the VIRGO observational study receiving first-line hormonal therapy or chemotherapy and/or targeted therapy for locally recurrent or metastatic breast cancer, the most common severe symptoms were of moderate-to-severe intensity in 38.8% to 52.0%, mean daily activity impairment was 30%, and work productivity impairment ranged from 20% to 40% among 58 employed participants. Average total time spent on health care ranged from 7% to 10% of all days in the first 3 months of treatment, depending on treatment. In a survey of 345 informal caregivers of people living with metastatic breast cancer in the United States, United Kingdom, and Germany, one in three changed work status after the onset of caregiving: 12% reduced working hours, 13% stopped working, and 8% increased working hours.

Summary: economic burden, family impact, and diagnostic testing costs

In one analysis, 3,203 participants received first-line, 2,194 second-line, and 1,242 third-line therapy for metastatic breast cancer; mean total healthcare costs per patient per month in the first, second, and third line were $6,521, $4,440, and $4,555 among those receiving endocrine therapy and $16,842, $12,868, and $16,129 among those receiving chemotherapy. Among 5,563 eligible participants in a second analysis, average monthly all-cause costs were $14,424 per patient, and 12-month indirect costs for short-term disability were $10,397 in participants with metastatic breast cancer, compared with $394 in matched noncancer participants. Using Medicare prices, the mean total per-patient treatment and supportive care drug cost for HR-positive, ERBB2-negative metastatic breast cancer was $104,774, and annual costs in year 1 for this subtype increased from $12,986 in 2011 to $80,563 in 2019. Among 5,709 participants with metastatic breast cancer, 56.8% had evidence of disease progression over 12 months, and per-patient-per-month costs were almost twice as high among progressors as among nonprogressors. Annualized cancer-attributable costs of medical care (Medicare Parts A and B) for breast cancer diagnosed at distant stage were $67.4 thousand in the initial phase, $22.3 thousand in the continuing phase, and $91.9 thousand in the end-of-life phase (2019 US dollars). Among 3,878 females in another analysis, the 18.5% who met end-of-life criteria had 6-month total healthcare costs of $72,112, compared with $17,137. Prevalence of metastatic breast cancer was projected to reach 246,194 cases in 2030, an increase of 54.8% from 158,997 in 2015, with total medical and productivity costs increasing from $63.4 billion in 2015 to $152.4 billion in 2030.

In the MarketScan Health and Productivity Management database (2005-2009), families of patients with metastatic breast cancer incurred 39.7% (p = 0.06) higher indirect costs than families of patients with early breast cancer. In a survey of 1,054 young adult women with metastatic cancer who responded from 41 states, 30% were uninsured, and uninsured participants were more likely than insured participants to report contact by debt collectors (adjusted risk ratio 2.38). Medicare pays $5,000.00 for Guardant360 CDx and $3,500.00 for FoundationOne Liquid CDx during the new Advanced Diagnostic Laboratory Test initial period. In one analysis, testing rates were approximately 32% at second line and 25% at third line across subgroups.

Palazestrant efficacy and safety

Summary: development status and pivotal trial design (OPERA-01)
  • Palazestrant is an investigational oral complete estrogen receptor antagonist and selective estrogen receptor degrader. The sponsor has no product approved for commercial sale. In July 2022, FDA granted Fast Track designation for ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor.
  • OPERA-01 (NCT06016738) is a global phase 3, randomized, open-label, active-controlled trial in men and women aged 18 years or older with ER+/HER2- locally advanced or metastatic breast cancer that progressed after endocrine therapy combined with a CDK4/6 inhibitor. One additional line of endocrine monotherapy is allowed, and participants who received chemotherapy in the advanced or metastatic setting, or prior elacestrant or an investigational estrogen receptor-directed therapy, are excluded.
  • In Part 1 (dose selection), approximately 120 participants were randomized 1:1:1 to palazestrant 90 mg or 120 mg once daily or standard-of-care endocrine therapy. The independent data monitoring committee recommended 90 mg, and the sponsor aligned with FDA on 90 mg as the Part 2 dose. In Part 2, participants are randomized 1:1 to palazestrant 90 mg once daily or the investigator's choice of fulvestrant or an aromatase inhibitor (letrozole, anastrozole, or exemestane). Randomization is stratified by ESR1 mutation status in circulating tumor DNA, prior lines of endocrine therapy for advanced disease (1 vs 2), and visceral disease.
  • The dual primary endpoint is PFS assessed by blinded independent central review, analyzed separately in participants with ESR1-mutated tumors and in participants without detectable ESR1 mutations; overall survival in the same two populations is a key secondary endpoint. Approximately 510 participants are planned, including 470 for the primary analysis. OPERA-01 participants receive a tablet formulation, whereas the phase 1/2 monotherapy data were obtained with capsules.
  • Enrollment began in November 2023 and is complete. No OPERA-01 efficacy or safety results have been reported. The sponsor anticipates top-line results in the first quarter of 2027, an NDA submission in 2027, and, if the trial is successful, potential FDA approval and commercial launch in 2028.
  • A second phase 3 trial, OPERA-02 (NCT07085767), compares palazestrant with ribociclib against letrozole with ribociclib in approximately 1,000 participants who have not received prior systemic treatment for advanced breast cancer, a population outside this indication. Top-line data are anticipated in 2028.
Summary: monotherapy efficacy (OP-1250-001)
  • OP-1250-001 (NCT04505826) was an open-label, multicenter, phase 1/2 study of single-agent palazestrant capsules taken once daily in the fasted state by participants with previously treated ER+/HER2- advanced or metastatic breast cancer. The peer-reviewed publication includes 146 participants enrolled at 15 sites in the US and Australia between August 2020 and November 2022, with a data cutoff of July 7, 2023. The study had no comparator arm.
  • During dose escalation, 42 participants received 30 to 300 mg/day; there were no dose-limiting toxicities, and the maximum tolerated dose was not reached. Exposure was dose-proportional from 30 to 300 mg/day, the effective half-life was approximately 70 h, and the terminal half-life was approximately 8 days. Doses of 60 and 120 mg/day were carried into dose expansion, and 120 mg/day was selected as the recommended phase 2 dose on the basis of a clinical benefit rate (CBR) of 46% at 120 mg/day and 19% at 60 mg/day.
  • Of the 116 participants treated at 60 or 120 mg/day, 95.7% had received a prior CDK4/6 inhibitor, 63.8% had received at least 2 prior lines of endocrine therapy in the advanced setting, and 51 of 96 with baseline circulating tumor DNA results (53.1%) had ESR1 mutations.
  • In the peer-reviewed publication, the 120 mg/day cohort (n = 86) had 3 confirmed partial responses (4.5%) and 2 unconfirmed partial responses (3.0%) among 66 response-evaluable participants, with one further confirmed partial response after the data cutoff (4 confirmed, 6.0%). The CBR was 45.7% (95% CI, 33.7 to 58.1) among 70 CBR-evaluable participants and 58.6% (95% CI, 38.9 to 76.5) among 29 CBR-evaluable participants with ESR1 mutations. Median PFS was 4.8 months (95% CI, 3.5 to 7.1) with a 6-month PFS rate of 39%; in participants with ESR1 mutations, median PFS was 5.6 months (95% CI, 4.8 to not estimable) with a 6-month PFS rate of 47%. In total, 32 of 86 participants (37.2%) remained on treatment for 6 months or longer. In the 60 mg/day cohort, the CBR was 19.2% (95% CI, 6.6 to 39.4) among 26 evaluable participants.
  • The 2023 conference presentation reports different values for the 120 mg cohort: a CBR of 40% (32/81) in all participants, 52% (17/33) with ESR1 mutations, and 32% (12/38) with ESR1 wild-type tumors, and a median PFS of 4.6 months (95% CI, 3.5 to 6.5) with a 6-month PFS rate of 38% in all 86 participants. The 2023 company announcement reports a median PFS of 3.5 months in participants with ESR1 wild-type tumors.
  • In a subset analysis of 49 participants who received palazestrant as second- or third-line therapy with or without prior chemotherapy, median PFS was 7.2 months and the CBR was 48%; among participants in this subset with ESR1 mutations, median PFS was 7.3 months and the CBR was 59%.
Summary: combination efficacy (OP-1250-003 and OP-1250-002)
  • OP-1250-003 (NCT05508906) is a phase 1b, open-label, 2-part study of palazestrant with ribociclib, alpelisib, everolimus, or atirmociclib. The ribociclib group allowed up to 2 prior endocrine therapies with or without a CDK4/6 inhibitor and up to 1 prior line of chemotherapy for advanced disease. At the July 8, 2025 data cutoff, 78 participants were enrolled in the ribociclib group and data were presented for 72: 56 received palazestrant 120 mg and 16 received 90 mg, all with ribociclib 600 mg. Of the 72, 24 (33%) had no prior line of therapy in the advanced setting, 45 (63%) had received a prior CDK4/6 inhibitor with endocrine therapy for advanced disease, and 15 of 69 (22%) had ESR1 mutations at baseline.
  • In the 120 mg cohort, median PFS was 15.5 months in all participants, 12.2 months in participants with a prior CDK4/6 inhibitor, 9.2 months in those with ESR1 wild-type tumors and a prior CDK4/6 inhibitor, and 13.8 months in those with ESR1-mutated tumors and a prior CDK4/6 inhibitor; median follow-up was 19.1 months in all participants and 19.8 months in those with a prior CDK4/6 inhibitor. In the 90 mg cohort, median follow-up was 10.8 months and median PFS was not reached.
  • Among response-evaluable participants with measurable disease, the objective response rate was 34% (15/44) overall, 31% (10/32) in the 120 mg cohort, 26% (6/23) in participants with a prior CDK4/6 inhibitor in the 120 mg cohort, and 42% (5/12) in the 90 mg cohort. Ribociclib had no clinically meaningful effect on palazestrant exposure, palazestrant had no clinically meaningful effect on ribociclib exposure, and exposure did not differ to a clinically significant degree between the 90 mg and 120 mg doses. Initial data from the atirmociclib group are expected in December 2026.
  • OP-1250-002 (NCT05266105) is an open-label, phase 1b dose-escalation and dose-expansion study of palazestrant with palbociclib 125 mg once daily on days 1 to 21 of each 28-day cycle, in participants with zero or one prior endocrine therapy with or without a CDK4/6 inhibitor for advanced disease. At the September 15, 2023 data cutoff, 46 participants were enrolled (37 at palazestrant 120 mg), and 33 (72%) had received a prior CDK4/6 inhibitor for advanced disease. Partial responses were observed in 7 participants (2 confirmed and 5 unconfirmed). The CBR was 46% (12/26) in all participants and 60% (6/10) in participants with ESR1 mutations; the company announcement reports a CBR of 71% in participants without prior CDK4/6 inhibitor treatment. Palbociclib 125 mg did not affect palazestrant exposure, and palazestrant did not affect palbociclib exposure.
Summary: safety
  • Monotherapy (OP-1250-001, peer-reviewed publication, 120 mg/day, n = 86): 95.3% of participants had at least one treatment-emergent adverse event (TEAE), most commonly nausea (62.8%), vomiting (29.1%), and fatigue (25.6%). Grade 3 TEAEs occurred in 21 participants (24.4%) and grade 4 TEAEs in 8 (9.3%), including neutropenia in 6. Grade 3 treatment-related adverse events occurred in 10 participants (11.6%), and treatment-related grade 4 neutropenia in 5 (5.8%). Treatment-related diarrhea of any grade occurred in 13%, with no grade 3 or higher events.
  • Grade 4 neutropenia: the publication states that the events occurred approximately 6 to 8 weeks after initiation, and the 2023 company announcement states approximately 4 to 6 weeks into therapy and that all 6 affected participants had prior CDK4/6 inhibitor exposure. In 3 of the 6, neutropenia resolved with a 1-week interruption followed by dose reduction, and in 3 it resolved after discontinuation. Ongoing studies monitor blood counts more frequently during the first 6 to 8 weeks of treatment.
  • Bradycardia (9%) and photopsia (5%) occurred at 120 mg/day; all events were grade 1 and led to no dose modifications, interruptions, or discontinuations. No QTcF value exceeded 500 ms. Among the 116 participants treated at 60 or 120 mg/day, 7 (6.0%) discontinued treatment for adverse events. The publication states that fasted administration, the exclusion of proton pump inhibitors and most common antiemetics, and a relatively large capsule could each have contributed to gastrointestinal events; OPERA-01 uses a tablet formulation.
  • The posted registry results list 83 participants at risk at 120 mg, with serious adverse events in 16 of 83 (19.28%), and serious febrile neutropenia in 2 of 83 (2.41%); aspartate aminotransferase increase was reported in 13 of 83 (15.66%).
  • Combination with ribociclib (OP-1250-003, July 2025 data cutoff): treatment-related neutropenia occurred in 47 of 56 participants (84%) at palazestrant 120 mg, grade 3 in 28 (50%) and grade 4 in 5 (9%), and in 13 of 16 (81%) at 90 mg, grade 3 in 9 (56%). Treatment-related QT prolongation on electrocardiogram occurred in 16 (29%) and 4 (25%), respectively. Two participants had dose reductions of palazestrant only, 8 of both drugs, and 23 of ribociclib only, most often for neutropenia. Three participants discontinued both drugs for a TEAE. Two participants had grade 5 adverse events, neither related to palazestrant.
  • Combination with palbociclib (OP-1250-002, September 2023 data cutoff, N = 46): neutropenia occurred in 40 participants (87%), grade 3 in 28 (61%) and grade 4 in 5 (11%), and nausea in 26 (57%). No participant had a palazestrant dose reduction for neutropenia, 11 had palbociclib dose reductions for neutropenia, and 1 discontinued both drugs for nausea concurrent with disease progression.

Budget impact of Palazestrant

Summary: price status
  • Palazestrant is investigational. Olema Oncology states that it has no product candidates “approved for commercial sale” and has not generated revenue from product sales, so no wholesale acquisition cost, average sales price, or FDA label exists. The company anticipates OPERA-01 top-line results in the first quarter of 2027, expects to submit the new drug application in 2027, and anticipates potential FDA approval and commercial launch in 2028.
  • Commercial launch planning began in 2025, and the company anticipates a targeted field force of approximately 75 to 100 representatives. No budget impact model or cost-effectiveness analysis of palazestrant has been published.
  • Company estimates of market size: “Based on our internal estimates”, the global ER+/HER2- metastatic breast cancer market represents approximately $20 billion, and the market potential for palazestrant in the U.S. and E.U. is up to $5 billion in the second- and third-line settings and up to $10 billion in the first-line setting. Alongside “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”, the corporate presentation gives an annual U.S. incidence “estimated at 40K” and a U.S. market potential of “$3-5B”, labeled as an “Olema internal estimate of US market.”
Summary: comparator prices and published economic evaluations
  • Elacestrant (Orserdu): wholesale acquisition cost at commercial availability on 2/3/2023 of $21,369.00 per 30 tablets of 345 mg and $7,123.00 per 30 tablets of 86 mg; the labeled dosage is 345 mg orally once daily. A U.S. model cited a cost of $22511.06 for 30 tablets of 345 mg, with unit costs from the Centers for Medicare & Medicaid Services and AWP&AAC Medicaid.
  • Imlunestrant (Inluriyo): wholesale acquisition cost of $11,250.00 per 28 tablets and $22,500.00 per 56 tablets of 200 mg (accessed 09/26/2025); the labeled dosage is 400 mg orally once daily.
  • Capivasertib (Truqap): wholesale acquisition cost of $22,922.00 per 4 x 16 blister package of 160 mg or 200 mg tablets; the labeled dosage, in combination with fulvestrant, is 400 mg orally twice daily for 4 days followed by 3 days off. A U.S. model in 2025 U.S. dollars, based on wholesale acquisition cost, used a capivasertib cost of $28,332 per 4 weeks.
  • Gedatolisib (Revtorpyk): $10,000 per vial, or $30,000 per 28-day cycle of treatment, as reported to the drug pricing compendia.
  • Fulvestrant: a U.S. health care perspective model with a monthly cycle length used 1,129.2 per cycle (range 903.36 to 1,355.04), with drug costs calculated from 2023 average sale price data of the Centers for Medicare & Medicaid Services.
  • U.S. cost-effectiveness analyses of comparators report incremental cost-effectiveness ratios of $8,672,360 per QALY gained for elacestrant compared with standard of care overall and $2,900,560 per QALY gained compared with fulvestrant in the ESR1-mutation subgroup; $128,283.61, $280,854, and $709,647 per QALY for capivasertib plus fulvestrant compared with fulvestrant alone in three models and $636,455 per QALY gained in the PIK3CA/AKT1/PTEN-altered subgroup in a fourth; and $340,153.30 per QALY gained for alpelisib plus fulvestrant. A U.S. budget impact analysis of capivasertib in the second line, in 2023 US dollars, estimated $31,939,838 in net costs over 3 years in a 1-million-member population, or $0.88 per member per month.
  • NICE recommends elacestrant for ESR1-mutated disease after at least 12 months of endocrine treatment plus a CDK4/6 inhibitor, under a commercial arrangement, with exact cost-effectiveness estimates confidential. NICE states that it is “unable to make a recommendation about the use in the NHS of imlunestrant” because the company “does not intend to make an evidence submission for the evaluation”, and gives as the reason that “the technology is unlikely to be a cost-effective use of NHS resources.” No Institute for Clinical and Economic Review assessment of therapies for this population was identified.
Summary: eligible population inputs
  • U.S. incidence and prevalence: about 321,910 new cases of invasive breast cancer will be diagnosed in women in 2026. SEER reports 6% of female breast cancer cases as distant stage at diagnosis (5-year relative survival 33.8%), an estimated 4,238,585 women living with female breast cancer in 2023, and HR+/HER2- as 70% of cases, with an age-adjusted rate of 92.9 new cases per 100,000 women based on 2019–2023 cases.
  • Metastatic disease: 169 347 individuals were projected to be living with metastatic breast cancer in the United States by January 1, 2025. For 2018, the estimated number of new metastatic female breast cancer cases, de novo and recurrence, was 46 666, of which 15 800 were observed de novo cases.
  • Company estimates: approximately 70% of breast cancers are ER+/HER2-, approximately 6-10% of patients present with metastatic disease at diagnosis, and a further 20-30% of patients diagnosed with early-stage disease ultimately develop metastatic disease. The corporate presentation gives an annual U.S. incidence “estimated at ~40K” alongside “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”.
  • Treatment after first-line CDK4/6 inhibitor therapy in one cohort: of 1210 participants who received a CDK4/6 inhibitor with endocrine therapy as first-line therapy from 2015 to 2020, 839 received a documented second-line therapy, which was cytotoxic chemotherapy in 249 (29.7%), endocrine monotherapy in 104 (12.4%; fulvestrant in 70, 8.3%), everolimus in 99 (11.7%), alpelisib in 16 (1.9%), and a PARP inhibitor in 4 (0.5%); 302 (36.0%) continued a CDK4/6 inhibitor.
  • Real-world progression-free survival: across 18 real-world studies, the weighted average median real-world progression-free survival in the second line after a first-line CDK4/6 inhibitor was 3.9 months for single-agent endocrine therapy, 3.6 months for mTOR inhibitor with or without endocrine therapy, and 6.1 months for chemotherapy.
  • ESR1 mutation and testing: OPERA-01 enrolls participants “regardless of ESR1 mutation status”, and palazestrant was dosed at 90 mg once daily in Part 2. ESR1 mutation prevalence in tissue biopsies near initiation of the first, second, and third lines was 8.1%, 27.1%, and 33.3%, and in liquid biopsies 10.4%, 37.6%, and 38.7%. In one analysis, testing rates were approximately 32% at the second line and 25% at the third line across subgroups. Medicare payment during the new Advanced Diagnostic Laboratory Test initial period is $5,000.00 for Guardant360 CDx (0242U) and $3,500.00 for FoundationOne Liquid CDx (0239U), and Medicare covers FDA-approved next-generation sequencing companion diagnostics nationally for recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer for services on or after March 16, 2018.

Conclusions

Summary: conclusions for formulary review
  • Regulatory status and timing: palazestrant is investigational, with no FDA-approved indication, prescribing information, or price; Olema Oncology has no product candidates “approved for commercial sale”. FDA granted Fast Track designation in July 2022 for ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. The company anticipates OPERA-01 top-line results in the first quarter of 2027, expects to submit the NDA in 2027, and anticipates potential FDA approval and commercial launch in 2028.
  • Pivotal trial: OPERA-01 (NCT06016738) is a phase 3, randomized, open-label trial that, in Part 2, compares palazestrant 90 mg once daily with investigator's choice of standard-of-care endocrine therapy (fulvestrant or an aromatase inhibitor) in participants whose disease progressed after endocrine therapy combined with a CDK4/6 inhibitor. Approximately 510 participants are planned, including 470 for the primary analysis. The dual primary endpoint is PFS by blinded independent central review, analyzed separately in participants with ESR1-mutated tumors and in participants without detectable ESR1 mutations; overall survival is a key secondary endpoint, and patient-reported outcomes (EQ-5D-5L and EORTC QLQ-C30) are secondary endpoints. Enrollment is complete, and no efficacy, safety, or patient-reported outcome results have been reported.
  • Monotherapy evidence base: all efficacy data for palazestrant monotherapy come from OP-1250-001 (NCT04505826), an open-label, multicenter phase 1/2 study without a comparator arm, a design the authors state limits interpretation of the safety profile and antitumor activity. These data were obtained with capsules taken in the fasted state, whereas OPERA-01 participants receive a tablet formulation, and only 6 participants were enrolled at the 90 mg dose selected for OPERA-01, all during dose escalation.
  • Monotherapy efficacy (OP-1250-001, peer-reviewed publication, data cutoff July 7, 2023): of the 116 participants treated at 60 or 120 mg/day, 95.7% had received a prior CDK4/6 inhibitor and 63.8% at least 2 prior lines of endocrine therapy in the advanced setting. In the 120 mg/day cohort (n = 86), 3 of 66 response-evaluable participants (4.5%) had a confirmed partial response, the CBR was 45.7% (95% CI, 33.7 to 58.1) among 70 CBR-evaluable participants and 58.6% (95% CI, 38.9 to 76.5) among 29 with ESR1 mutations, and median PFS was 4.8 months (95% CI, 3.5 to 7.1) overall and 5.6 months (95% CI, 4.8 to not estimable) with ESR1 mutations. The 60 mg/day cohort had a CBR of 19.2% (95% CI, 6.6 to 39.4) among 26 evaluable participants. The 2023 conference presentation of the 120 mg cohort reports a CBR of 40% (32/81) and a median PFS of 4.6 months.
  • Combination evidence comes from two open-label phase 1b studies: with ribociclib (OP-1250-003, July 8, 2025 data cutoff, 72 participants presented, 24 of whom (33%) had no prior line of therapy in the advanced setting), median PFS in the 120 mg cohort was 15.5 months in all participants and 12.2 months in those with a prior CDK4/6 inhibitor, the objective response rate was 34% (15/44) among response-evaluable participants with measurable disease, and median PFS was not reached in the 90 mg cohort at a median follow-up of 10.8 months. With palbociclib (OP-1250-002, September 15, 2023 data cutoff, 46 participants), the CBR was 46% (12/26).
  • Safety: in the 120 mg/day monotherapy cohort (n = 86), the most common treatment-emergent adverse events were nausea (62.8%), vomiting (29.1%), and fatigue (25.6%); 8 participants (9.3%) had grade 4 events, including neutropenia in 6, and treatment-related grade 4 neutropenia occurred in 5 (5.8%). Bradycardia (9%) and photopsia (5%) were all grade 1, no QTcF value exceeded 500 ms, and 7 of 116 participants (6.0%) at 60 or 120 mg/day discontinued for adverse events. Ongoing studies monitor blood counts more frequently during the first 6 to 8 weeks. With ribociclib at palazestrant 120 mg, treatment-related neutropenia occurred in 47 of 56 participants (84%), grade 3 in 28 (50%) and grade 4 in 5 (9%), and treatment-related QT prolongation on electrocardiogram in 16 (29%).
  • Studied population relative to approved oral endocrine agents: elacestrant, imlunestrant, and vepdegestrant are indicated for ESR1-mutated disease after at least one line of endocrine therapy, and each label directs selection of patients “based on the presence of ESR1 mutation(s)” in a plasma specimen. OPERA-01 enrolls participants “regardless of ESR1 mutation status”, and the company states that “Palazestrant’s approval in ESR1 mutant and wild-type tumors in the 2/3L ER+/HER2- MBC setting would be paradigm-shifting”. Without ESR1 mutations, the PFS hazard ratio for elacestrant was 0.86 (95% CI, 0.63 to 1.19) in an exploratory analysis of 250 participants, and median PFS was 5.6 months with imlunestrant and 5.7 months with standard therapy (hazard ratio 1.00). In OP-1250-001, 51 of 96 participants with baseline circulating tumor DNA results (53.1%) had ESR1 mutations; in the 120 mg cohort, the conference presentation reports a CBR of 32% (12/38) and the 2023 company announcement a median PFS of 3.5 months in participants with ESR1 wild-type tumors.
  • Price and economic evidence: no wholesale acquisition cost, budget impact model, or cost-effectiveness analysis of palazestrant has been published. Comparator wholesale acquisition costs are $21,369.00 per 30 tablets of elacestrant 345 mg and $22,500.00 per 56 tablets of imlunestrant 200 mg, and a U.S. third-party payer model estimated an ICER of $8,672,360 per QALY gained for elacestrant compared with standard of care in the overall population. The corporate presentation gives an annual U.S. incidence “estimated at ~40K” alongside “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”.
  • Evidence not yet available for review: OPERA-01 PFS results in the ESR1-mutated and ESR1 mutation-not-detected populations, overall survival, patient-reported outcomes, and safety with the 90 mg tablet in a randomized comparison; FDA-approved prescribing information, including the indicated population; a wholesale acquisition cost; and a budget impact or cost-effectiveness analysis of palazestrant.